Pancreatic neuroendocrine tumours (pNETs) are a rare form of pancreatic cancer. Several therapeutic options exist for pNETS; however, there is no algorithm to determine the optimum sequence of therapies. Approved treatments for pNETs include somatostatin analogues (SSAs), streptozocin-based chemotherapy and targeted therapies such as everolimus and sunitinib. Unapproved therapies include systemic peptide receptor-targeted radiotherapy (PRRT), temozolomide-based chemotherapy, liver resection, liver transplantation, hepatic artery embolisation with or without chemotherapy and selective internal radiation therapy (SIRT). An individualised approach to the treatment of pNETs is described. Firstly, it is necessary to decide whether it is appropriate to treat at all. For those wi th symptoms, it is necessary to define the treatment goal: symptomatic or oncological control. Symptoms may direct treatment decisions; for example in patients with hypogycaemia, everolimus would be the most effective therapy. In high-volume disease where tumour reduction is the highest priority, streptozocin-based chemotherapy would be a more appropriate choice. For patients with disease progression and a moderate-to-high tumour volume, targeted therapy is the preferred choice. Following the failure of first-line therapies, second -line options include other targeted agents and cytotoxic chemotherapy. PRRT is recommended only after failure of prior therapy. Treatment decisions of pNETs should be made in a patient-oriented manner and on a case-by-case basis.
Pancreatic neuroendocrine tumours (pNETs), also known as islet cell tumours, arise from the pancreatic islet of Langerhans and can be divided into functioning and non-functioning tumours based on whether they are associated with hormonal syndromes caused by excess hormone or peptide secretion. Functioning pNETs can be responsible for a variety of clinical syndromes: Zollinger-Ellison syndrome is caused by gastrinomas (tumours that oversecrete gastrin), insulinomas are pNETs that overproduce insulin or proinsulin and glucagonomas overproduce glucagon and enteroglucagon. Other hormonal syndrome tumour types include: vasoactive intestinal peptide-producing tumours (VIPomas), pancreatic polypeptidomas (PPomas), and somatostatinomas. 1 pNETs account for only 1.3 % of all pancreatic cancer. 2 Estimates of incidence vary but the most recent published data suggest an annual incidence of 1-3 per million individuals, per year. [3] [4] [5] [6] Data from 1,185
cases of pNETs from the surveillance, epidemiology and end results (SEER) database was used to further examine the epidemiology of this tumour type. Distribution of cancer stage for pNETs at diagnosis included 14 % localised, 23 % regional and 54 % distant or metastatic. 2 The median survival rate for patients with localised pNETs was not reached, however, the 5-year survival rate was 79 %. 6 in patients with regional stage disease, the median survival was 111 months and the five-year survival rate was 62 %. These numbers were further reduced in patients with distant metastatic disease, with a median survival rate of 27 months and a five-year survival rate of 27 %.
Although the majority of pNETs occur sporadically, pNETs can arise in association with several hereditary cancer syndromes. Approximately 10 % may be connected with multiple endocrine neoplasia type 1 (MEN1), 7 an autosomal dominant inherited disorder characterised by mutations in the menin tumour suppressor gene and development of tumours of the pancreas, parathyroid and pituitary. In addition to MEN1, other genetic cancer syndromes associated with pNETs include: von Hippel-Lindau (vHL) disease, tuberous sclerosis and neurofibromatosis. A recent study determined the exomic sequences of ten non-familial pNETs to explore the genetic basis of sporadic disease. 8 The commonly mutated genes were then screened against an additional 58 pNETs and it was determined that, within the 68 pNETs analysed, 43 % had alterations in DAXX (death-domain associated protein) or ATRX (alpha thalassemia/mental retardation syndrome X-linked) which encode subunits of a transcription/chromatin remodelling complex. A total of 44 % contained mutations in MEN1, the menin tumour suppressor gene and 14 % had mutations affecting genes within the mammalian target of rapamycin (mTOR) pathway.
These molecular associations suggest three key pathways are involved in the development of pNETs. The first involves menin and its role in cell cycle Table 1 ).
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The reported tumour response rate for streptozocin and doxorubicin was 69 %, and was due in part to the historical use of non-standard response rates, which differ from the currently used WHO/RECIST criteria. This use of non-standard response rates also means that there are no reliable data outlining progression-free survival rates in patients following treatment with streptozocin, alone or in combination.
In addition to the paucity of data demonstrating efficacy of this treatment regime, there is a lack of robust safety data (using modern criteria suggested that the benefit gained from everolimus treatment with respect to increased progression-free survival was primarily due to disease stabilisation, minor tumour shrinkage or a lower incidence of progressive disease. No differences in overall survival (OS) were observed due to the preplanned crossover to everolimus following disease progression of those in the placebo arm. Median overall survival was not reached, but was >32 months at the time of analysis. In addition to the demonstrated efficacy of everolimus, data suggest that everolimus treatment may reduce hormonal secretion from tumours.
Furthermore, the use of everolimus in four patients with insulinoma and refractory hypoglycaemia was demonstrated to improve glycaemia control. 23 Treatment with everolimus has also been noted to decrease serum levels of gastrin and glucagon in patients with pNET, 42 In a Phase II clinical trial of 66 patients with advanced pNET (n=66), the ORR was 16.7 %, 68 % had stable disease and the median time to tumour progression was 7.7 months. 31 These positive results were the basis of a Phase III, randomised, double-blind, trial of sunitinib versus placebo which was ended early, due to significant differences in disease progression and deaths in the placebo group. 33 A total of 171 patients were enrolled in the trial, 86 receiving sunitinib (37.5 mg daily) and 85 receiving placebo.
The median PFS in the sunitinib treatment was group was 11. Examination of the baseline patient characteristics from this Phase III trial shows some imbalance in prognostic factors, with differences in performance status and in the number of metastatic sites. 33 In the sunitinib arm, 62 % of patients had an ECOG performance status score of 0 and 38% had a score of 1, while in the placebo arm 48 % scored 0 and 51 % scored 1. Additionally, 28 % of those in the sunitinib arm had more than three sites of disease, compared with 41 % of those in the placebo arm. Early termination of the study may have led to an overestimation of efficacy (in comparison, the median time to progression [TTP] for sunitinib in a Phase II study was only 7.7 months). 31, 43 This also means that the false-positive rate was not controlled for and PFS did not cross the Lan-DeMets and O'Brien-Fleming efficacy boundary for statistical significance. In the initial report of the Phase III study, it was suggested that sunitinib provided a possible benefit in overall survival; 33 however, analysis subsequent to a longer follow up period found no difference in overall survival between the sunitinib and placebo arms. 32 The safety data obtained for sunitinib are not as robust as those obtained for everolimus due to the short exposure duration in the Phase III sunitinib trial. The most common side effects were diarrhoea (59 %), fatigue (32 %), nausea (45 %), asthenia (34 %) and vomiting (34 %), while the most frequent grade 3-4 adverse events consisted of neutropenia (12 %), hypertension (10 %), hand-foot syndrome (6 %), and leukopenia (6 %). 33 Sunitinib appears to be better tolerated when dosed at 37.5 mg/day; at doses of 50 mg/day, 89 % of patients reported fatigue and 62.6 % of patients had at least one dosing interruption. 31 Although cardiotoxicity was not reported in either of these studies, it has been previously associated with sunitinib use 44 and patients with cardiac risk factors should be closely monitored.
Unapproved Options
With a few exceptions, there is a paucity of large, randomised, prospective studies to evaluate the efficacy of these treatments and few approved treatments for pNETS. Although many of the following unapproved treatment options are used widely, there are scant data available to make evidence-based decisions on appropriate treatment choices. 
Peptide Receptor Radionuclide Therapy

Temozolomide-based Chemotherapy
Temozolomide is an oral cytotoxic alkylating agent, with a mechanism of action similar to that of streptozocin. Reported survival rates for this surgical approach are >60 % at five years, which is double that of patients with untreated liver metastases.
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Liver Transplantation
Liver transplantation is considered an experimental treatment option with unproven benefit. 50 In a retrospective study of 103 individuals who underwent orthotopic liver transplant (OLT) by Lehnert, the 2-year and 5-year survival was 60 % and 47 %, respectively, however recurrence-free 5-year survival did not exceed 24 %. 51 It has been noted in several studies that pNETs have worse outcomes following OLT than more indolent NETs. 51, 52 As with other unapproved treatments for pNETs, further large prospective studies are warranted to demonstrate whether there is a substantial benefit to this treatment. OLT is not indicated for patients with pNETs based on the current level of evidence. In addition, an echocardiogram should be considered before use in patients who have been treated with prior cardiotoxic chemotherapy.
Second-line Therapies
Following failure of first-line treatment, the choices of second-line therapy include alternate targeted agents, and cytotoxic chemotherapy.
PRRT is only recommended after failure of medical therapy by an ENETs expert consensus panel. 56 Due to concern for long-term bone marrow and renal toxicities that may hinder therapeutic options, however, PRRT should be employed following failure of prior therapy. For patients with slowly progressive disease that reached high volume or with hormonal symptoms, hepatic artery embolisation, hepatic artery chemoembolisation, or SIRT is recommended.
Conclusions
There is currently an increasing number of therapeutic options available 
